Pacific Biosciences
PACB
About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Employees: 575
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
7% less capital invested
Capital invested by funds: $265M [Q1] → $246M (-$19.6M) [Q2]
8% less funds holding
Funds holding: 221 [Q1] → 204 (-17) [Q2]
9.44% less ownership
Funds ownership: 75.57% [Q1] → 66.13% (-9.44%) [Q2]
18% less call options, than puts
Call options by funds: $2.16M | Put options by funds: $2.62M
22% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 69
33% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 45
50% less funds holding in top 10
Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Piper Sandler
David Westenberg
|
$1.5
|
Neutral
Maintained
|
11 Aug 2025 |
|
Barclays
Luke Sergott
|
$1.5
|
Equal-Weight
Maintained
|
25 Jun 2025 |
Financial journalist opinion
Based on 4 articles about PACB published over the past 30 days
